On January 10, 2025, Sichuan Jiuzhang Biotech and Miskawaan Health Group (MHG) held an academic exchange in Bangkok focused on the mechanistic research of botanical medicines in the treatment of tumors, immune-related diseases, antioxidation, and integrative medicine.

This visit was led by Dr. Rawiwan Charoensub, a professor at the Faculty of Pharmacy and Director of the Center for Research and Development of Herbal Medicine of Mae Fah Luang University in Thailand. The members included Mr. Yoo Seung Kim and Ms. Kawinyarat Mardpiratchata, with a total of more than 20 people in the delegation. They explored the application prospects of herbal medicine in the fields of holistic treatment and functional medicine, and reached important consensus on future cooperation.

On February 10, 2025, Miao Wei, Secretary of Chengdu Industrial Investment, and his entourage visited Sichuan Jiuzhang Biotech, where they engaged in a discussion and exchange.

On September 7, 2024, Miskawaan Health Group (hereinafter referred to as “Miskawaan Health Group”) signed an exclusive cooperation agreement with the senior management of Sichuan Jiuzhang Biological Science and Technology Co., Ltd. (herein after referred to as “Jiuzhang Biotech”), authorizing Miskawaan Health Group to import, distribute and use the patented chlorogenic acid products of Jiuzhang Biotech in Thailand.

To effectively address the global aging trend and advance research and innovation in longevity medicine, the Global Symposium on Longevity Medicine was held at Shenzhen Lansheng Brain Hospital on August 24.

On September 25, 2021, the highly anticipated 6th China Pharmaceutical Innovation and Investment Conference was successfully held in Suzhou. At this venture capital conference, Jiuzhang Biotech reported on-site the discovery process of the target of chlorogenic acid and the progress of the Phase I/II clinical trials for the treatment of recurrent glioblastoma.